Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate added to standard immunosuppression for prevention of liver allograft rejection
ISRCTN58758525Phase 2Completed
- Sponsor
- United States Department of Health and Human Services
- Start
- Jan 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised trial of methotrexate in Hepatic transplant rejection (LTR) (2 arms), sponsored by United States Department of Health and Human Services. Primary endpoints: Adverse effects attributable to immunosuppressant therapy and Incidence and severity of early graft rejection episodes. Started Jan 2004; status: completed.
02
Drugs
methotrexate
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on ISRCTN58758525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58758525.